Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Salona Global Medical Device ( (TSE:EVMT) ) just unveiled an announcement.
Evome Medical Technologies Inc. has significantly reduced its debt from $6.7 million to $4.25 million and extended repayment terms to April 2030, strengthening its financial position. This debt reduction and restructuring allow Evome greater financial flexibility, enabling capital raising, strategic M&A activities, and focusing on high-margin business lines. This move is a significant milestone in its restructuring strategy, improving the debt-to-equity ratio and stability, aiding in expanding product offerings, investing in innovation, and executing its long-term vision.
More about Salona Global Medical Device
Evome Medical Technologies Inc. specializes in human performance and rehabilitative solutions through strategic acquisitions and leveraging specialized companies’ intellectual properties. With a goal to create a large, broad-based medical device company with global reach, Evome operates through its subsidiaries, including Biodex, known for its innovative rehabilitation solutions serving orthopedic, sports medicine, and neurorehabilitation needs. Biodex offers advanced equipment like balance and mobility systems and isokinetic testing devices, with a presence in over 70 countries and partnerships with 52 distributors.
YTD Price Performance: -34.48%
Average Trading Volume: 102,133
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$7.89M
See more data about EVMT stock on TipRanks’ Stock Analysis page.